Fennec announces new PEDMARK research to be presented at 2026 ASCO Annual Meeting
Fennec Pharmaceuticals said on May 21, 2026 that new research on PEDMARK across several patient populations and tumor types will be presented at the 2026 American Society of Clinical Oncology Annual Meeting. The filing contains no financial results, guidance, or financial figures, so it is a clinical and research update rather than a measure of company performance.
Key points
- Four independently led studies will be shared at the ASCO Annual Meeting, covering adolescent, young adult and adult patients as well as pediatric patients.
- The Japanese Phase 2/3 STS-J01 study enrolled 27 patients and reported hearing loss of 16-24% with PEDMARK versus 56-63% with cisplatin alone, per the filing's historical comparison.
- A randomized Phase 1 trial for men with metastatic germ cell tumors, opened to accrual by City of Hope in January 2026, will present its trial design.
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 22, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.